PTEN and cancer: The antiproliferative activity of synthesized hybrids was tested using four cancer lines: HeLa (cervical carcinoma), MDA-MB-231 (ER-negative breast cancer), MCF-7 (ER-positive breast cancer), MDA-MB-468 (PTEN mutated breast cancer), and a non-cancer breast epithelial cell line 184B5.